MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Disease progression of spinocerebellar ataxia types 1, 2, 3, and 6 before and after ataxia onset: a joint analysis of two longitudinal cohort studies

    H. Jacobi, T. Schaprian, M. Schmid, T. Klockgether (Heidelberg, Germany)

    Objective: The aim was to model the evolution of ataxia and neurological symptoms in SCA1, SCA2, SCA3, and SCA6 over the entire disease span and…
  • 2023 International Congress

    Application of multi-parametric diffusion MRI in detecting visual disturbances in advanced Parkinson’s disease population

    K. Shivok, I. Ailes, M. Syed, I. Shelley, A. Alhussein, I. Fayed, T-W. Liang, C. Wu, A. Sharan, F. Mohamed, R. Sergott, L. Krisa, M. Alizadeh (Philadelphia, USA)

    Objective: We aimed to identify differences in multi-parametric diffusion indices (DTI, NODDI, and DKI) between Parkinson’s disease patients with visual disturbances and those without. Background:…
  • 2023 International Congress

    Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report

    K. Senkevich, I. Miliukhina, A. Zhuravlev, M. Shumilova, M. Beletskaia, A. Tyurin, M. Grunina, A. Rybakov, J. Ahmad, F. Asayesh, A. Timofeeva, Z. Gan-Or, A. Emelyanov, S. Pchelina (Montreal, Canada)

    Objective: To report a family with autosomal dominant Parkinson’s disease (PD) with SNCA p.E46K variant. Background: Alpha-synuclein, encoded by SNCA, is a part of Lewy…
  • 2023 International Congress

    Clebopride-induced Rabbit Syndrome: A Case Report.

    IA. Ortiz-Marroquin, E. Valdez-Rodriguez, V. Rodriguez-Martinez, D. Martinez-Ramirez (Monterrey, Mexico)

    Objective: This report aims to present a case of rabbit syndrome attributed to clebopride and to highlight the importance of considering nonneuroleptic drugs as a…
  • 2023 International Congress

    Trends in the evaluation and management of constipation in patients with Parkinson disease

    L. Deuel, W. Wright, E. Houston (Burlington, USA)

    Objective: Explore common evaluation and management strategies for constipation in patients with Parkinson disease (PD) at a tertiary center. Background: PD is diagnosed based on…
  • 2023 International Congress

    The diagnosis value of dopaminergic responsiveness of Parkinson’s disease: a systematic review and meta-analysis

    WY. Kou, HH. Cai, FT. Feng (beijiing, China)

    Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…
  • 2023 International Congress

    Case report on heterozygous OPA3 gene mutation causing ataxia

    J. Ng, T. Stiep (San Francisco, USA)

    Objective: To describe a case of adult-onset ataxia with a heterozygous p.Lys10Asn OPA3 mutation. Background: Mutations in the OPA3 gene, which encodes a mitochondrial membrane…
  • 2023 International Congress

    Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson’s disease with preceding REM sleep behavior disorders

    KA. Woo, HJ. Chang, JY. Joo, JH. Shin, SY. Kim, SM. Lee, BR. Jin, HY. Jeon, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

    Objective: To investigate the differences in the pattern of nigrostriatal and pontine monoaminergic degeneration patients with de novo Parkinson's disease (PD), stratified by the presence…
  • 2023 International Congress

    The prevalence and characteristics of REM sleep behavior disorder in progressive supranuclear palsy patients.

    APH. Phoumindr, JSR. Srignean, RBH. Bhidayasiri (Bangkok, Thailand)

    Objective: To describe the prevalence and characteristics of RBD in patients diagnosed with PSP and to demonstrate the association with each PSP subtype. Background: Rapid…
  • 2023 International Congress

    Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease

    T. Kustermann, G. Pagano, H. Svoboda, T. Nikolcheva, K. Taylor (Basel, Switzerland)

    Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…
  • « Previous Page
  • 1
  • …
  • 87
  • 88
  • 89
  • 90
  • 91
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley